Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"
Gespeichert in:
| Veröffentlicht in: | Cancer prevention research (Philadelphia, Pa.) Pa.), 2008-08, Vol.1 (3), p.215-216 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 3 |
| container_start_page | 215 |
| container_title | Cancer prevention research (Philadelphia, Pa.) |
| container_volume | 1 |
| creator | Stevens, Richard G Pretlow, Theresa P Hurlstone, D Paul Giardina, Charles Rosenberg, Daniel W |
| description | |
| doi_str_mv | 10.1158/1940-6207.CAPR-08-0094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69950561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69950561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c24b2e9e4380c8eef4d8b5bd87631eaf558d4d2261e5c296a0487d756faa583a3</originalsourceid><addsrcrecordid>eNptkc1u1TAQhSMEoqXwCtXoLtil2Ens2OyursqPVAnEz9qa2BNqlNjB9gX6WjwhiXoFm65mNHPOmZG-qrrk7IpzoV5x3bFaNqy_Ouw_fqqZqhnT3aPq_LTg4vG_nvVn1bOcvzMmG9W0T6szrnmrtNDn1Z9DnGcKBRK9ht3nJSZ03gIOlBKuY5vulgJjtB4wEYRYACEfU4rfsBBQcEv0YVMksHGKiWzBCdBRiDPCkujnmu5j2AEGB7v9A8E-QLmlBzzwy5dbsDSRjb_9ACV5nHbPqycjTplenOpF9fXN9ZfDu_rmw9v3h_1NbVvRl9o23dCQpq5VzCqisXNqEINTvWw54SiEcp1rGslJ2EZLZJ3qXS_kiChUi-1F9fI-d0nxx5FyMbPP6zMTBorHbKTWggnJV6G8F9oUc040miX5GdOd4cxstMwGwmwgzEbLMGU2Wqvx8nThOMzk_ttOeNq_jpmUjg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69950561</pqid></control><display><type>article</type><title>Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Stevens, Richard G ; Pretlow, Theresa P ; Hurlstone, D Paul ; Giardina, Charles ; Rosenberg, Daniel W</creator><creatorcontrib>Stevens, Richard G ; Pretlow, Theresa P ; Hurlstone, D Paul ; Giardina, Charles ; Rosenberg, Daniel W</creatorcontrib><identifier>ISSN: 1940-6207</identifier><identifier>EISSN: 1940-6215</identifier><identifier>DOI: 10.1158/1940-6207.CAPR-08-0094</identifier><identifier>PMID: 19138959</identifier><language>eng</language><publisher>United States</publisher><subject>Adenoma - diagnosis ; Adenoma - pathology ; Adenoma - prevention & control ; Antineoplastic Agents - therapeutic use ; Biomarkers - analysis ; Celecoxib ; Chemoprevention - methods ; Clinical Trials as Topic ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - prevention & control ; Consensus ; Early Detection of Cancer ; Humans ; Intestinal Mucosa - pathology ; Precancerous Conditions - diagnosis ; Precancerous Conditions - pathology ; Pyrazoles - therapeutic use ; Sulfonamides - therapeutic use</subject><ispartof>Cancer prevention research (Philadelphia, Pa.), 2008-08, Vol.1 (3), p.215-216</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-c24b2e9e4380c8eef4d8b5bd87631eaf558d4d2261e5c296a0487d756faa583a3</citedby><cites>FETCH-LOGICAL-c357t-c24b2e9e4380c8eef4d8b5bd87631eaf558d4d2261e5c296a0487d756faa583a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19138959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stevens, Richard G</creatorcontrib><creatorcontrib>Pretlow, Theresa P</creatorcontrib><creatorcontrib>Hurlstone, D Paul</creatorcontrib><creatorcontrib>Giardina, Charles</creatorcontrib><creatorcontrib>Rosenberg, Daniel W</creatorcontrib><title>Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"</title><title>Cancer prevention research (Philadelphia, Pa.)</title><addtitle>Cancer Prev Res (Phila)</addtitle><subject>Adenoma - diagnosis</subject><subject>Adenoma - pathology</subject><subject>Adenoma - prevention & control</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomarkers - analysis</subject><subject>Celecoxib</subject><subject>Chemoprevention - methods</subject><subject>Clinical Trials as Topic</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - prevention & control</subject><subject>Consensus</subject><subject>Early Detection of Cancer</subject><subject>Humans</subject><subject>Intestinal Mucosa - pathology</subject><subject>Precancerous Conditions - diagnosis</subject><subject>Precancerous Conditions - pathology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Sulfonamides - therapeutic use</subject><issn>1940-6207</issn><issn>1940-6215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc1u1TAQhSMEoqXwCtXoLtil2Ens2OyursqPVAnEz9qa2BNqlNjB9gX6WjwhiXoFm65mNHPOmZG-qrrk7IpzoV5x3bFaNqy_Ouw_fqqZqhnT3aPq_LTg4vG_nvVn1bOcvzMmG9W0T6szrnmrtNDn1Z9DnGcKBRK9ht3nJSZ03gIOlBKuY5vulgJjtB4wEYRYACEfU4rfsBBQcEv0YVMksHGKiWzBCdBRiDPCkujnmu5j2AEGB7v9A8E-QLmlBzzwy5dbsDSRjb_9ACV5nHbPqycjTplenOpF9fXN9ZfDu_rmw9v3h_1NbVvRl9o23dCQpq5VzCqisXNqEINTvWw54SiEcp1rGslJ2EZLZJ3qXS_kiChUi-1F9fI-d0nxx5FyMbPP6zMTBorHbKTWggnJV6G8F9oUc040miX5GdOd4cxstMwGwmwgzEbLMGU2Wqvx8nThOMzk_ttOeNq_jpmUjg</recordid><startdate>200808</startdate><enddate>200808</enddate><creator>Stevens, Richard G</creator><creator>Pretlow, Theresa P</creator><creator>Hurlstone, D Paul</creator><creator>Giardina, Charles</creator><creator>Rosenberg, Daniel W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200808</creationdate><title>Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"</title><author>Stevens, Richard G ; Pretlow, Theresa P ; Hurlstone, D Paul ; Giardina, Charles ; Rosenberg, Daniel W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c24b2e9e4380c8eef4d8b5bd87631eaf558d4d2261e5c296a0487d756faa583a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adenoma - diagnosis</topic><topic>Adenoma - pathology</topic><topic>Adenoma - prevention & control</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomarkers - analysis</topic><topic>Celecoxib</topic><topic>Chemoprevention - methods</topic><topic>Clinical Trials as Topic</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - prevention & control</topic><topic>Consensus</topic><topic>Early Detection of Cancer</topic><topic>Humans</topic><topic>Intestinal Mucosa - pathology</topic><topic>Precancerous Conditions - diagnosis</topic><topic>Precancerous Conditions - pathology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stevens, Richard G</creatorcontrib><creatorcontrib>Pretlow, Theresa P</creatorcontrib><creatorcontrib>Hurlstone, D Paul</creatorcontrib><creatorcontrib>Giardina, Charles</creatorcontrib><creatorcontrib>Rosenberg, Daniel W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer prevention research (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stevens, Richard G</au><au>Pretlow, Theresa P</au><au>Hurlstone, D Paul</au><au>Giardina, Charles</au><au>Rosenberg, Daniel W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial"</atitle><jtitle>Cancer prevention research (Philadelphia, Pa.)</jtitle><addtitle>Cancer Prev Res (Phila)</addtitle><date>2008-08</date><risdate>2008</risdate><volume>1</volume><issue>3</issue><spage>215</spage><epage>216</epage><pages>215-216</pages><issn>1940-6207</issn><eissn>1940-6215</eissn><cop>United States</cop><pmid>19138959</pmid><doi>10.1158/1940-6207.CAPR-08-0094</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1940-6207 |
| ispartof | Cancer prevention research (Philadelphia, Pa.), 2008-08, Vol.1 (3), p.215-216 |
| issn | 1940-6207 1940-6215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69950561 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adenoma - diagnosis Adenoma - pathology Adenoma - prevention & control Antineoplastic Agents - therapeutic use Biomarkers - analysis Celecoxib Chemoprevention - methods Clinical Trials as Topic Colorectal Neoplasms - diagnosis Colorectal Neoplasms - pathology Colorectal Neoplasms - prevention & control Consensus Early Detection of Cancer Humans Intestinal Mucosa - pathology Precancerous Conditions - diagnosis Precancerous Conditions - pathology Pyrazoles - therapeutic use Sulfonamides - therapeutic use |
| title | Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial" |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A42%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comment%20re:%20%22Sporadic%20aberrant%20crypt%20foci%20are%20not%20a%20surrogate%20endpoint%20for%20colorectal%20adenoma%20prevention%22%20and%20%22Aberrant%20crypt%20foci%20in%20the%20adenoma%20prevention%20with%20celecoxib%20trial%22&rft.jtitle=Cancer%20prevention%20research%20(Philadelphia,%20Pa.)&rft.au=Stevens,%20Richard%20G&rft.date=2008-08&rft.volume=1&rft.issue=3&rft.spage=215&rft.epage=216&rft.pages=215-216&rft.issn=1940-6207&rft.eissn=1940-6215&rft_id=info:doi/10.1158/1940-6207.CAPR-08-0094&rft_dat=%3Cproquest_cross%3E69950561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69950561&rft_id=info:pmid/19138959&rfr_iscdi=true |